Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 3/2017

04.12.2017 | Methotrexat | Leitlinien

S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

verfasst von: Dr. Jan Henrik Schirmer, Peer M. Aries, Kirsten de Groot, Bernhard Hellmich, Julia U. Holle, Christian Kneitz, Ina Kötter, Peter Lamprecht, Ulf Müller-Ladner, Eva Reinhold-Keller, Christof Specker, Michael Zänker, Frank Moosig

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 3/2017

Einloggen, um Zugang zu erhalten

Auszug

Die Medizin unterliegt einer fortlaufenden Entwicklung. Die dargestellten Angaben und Empfehlungen können stets nur den durch die Literaturrecherche abgedeckten Zeitraum berücksichtigen. Alle Empfehlungen wurden mit größtmöglicher Sorgfalt erstellt. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Aasarød K, Iversen BM, Hammerstrøm J et al (2000) Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 15:611–618PubMedCrossRef Aasarød K, Iversen BM, Hammerstrøm J et al (2000) Wegener’s granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 15:611–618PubMedCrossRef
2.
Zurück zum Zitat Aasarød K, Bostad L, Hammerstrøm J et al (2001) Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 16:953–960PubMedCrossRef Aasarød K, Bostad L, Hammerstrøm J et al (2001) Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 16:953–960PubMedCrossRef
3.
Zurück zum Zitat Abdou NI, Kullman GJ, Hoffman GS et al (2002) Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 29:309–316PubMed Abdou NI, Kullman GJ, Hoffman GS et al (2002) Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 29:309–316PubMed
4.
Zurück zum Zitat Agency for Health Care Policy and Research, Department of Health and Human Services (1992) Acute pain management: operative or medical procedures and trauma. Clinical practice guideline, Bd. no. 1. AHCPR Publ, Rockv, S 100–107 Agency for Health Care Policy and Research, Department of Health and Human Services (1992) Acute pain management: operative or medical procedures and trauma. Clinical practice guideline, Bd. no. 1. AHCPR Publ, Rockv, S 100–107
6.
Zurück zum Zitat Allen A, Pusey C, Gaskin G (1998) Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 9:1258–1263PubMed Allen A, Pusey C, Gaskin G (1998) Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 9:1258–1263PubMed
7.
8.
Zurück zum Zitat Arbach O, Gross WL, Gause A (2002) Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206:496–501PubMedCrossRef Arbach O, Gross WL, Gause A (2002) Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 206:496–501PubMedCrossRef
11.
Zurück zum Zitat Azar L, Springer J, Langford CA, Hoffman GS (2014) Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener’s): a retrospective single-center study. Arthritis Rheumatol 66:2862–2870. https://doi.org/10.1002/art.38744 PubMedCrossRef Azar L, Springer J, Langford CA, Hoffman GS (2014) Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener’s): a retrospective single-center study. Arthritis Rheumatol 66:2862–2870. https://​doi.​org/​10.​1002/​art.​38744 PubMedCrossRef
17.
Zurück zum Zitat Birck R, Warnatz K, Lorenz HM et al (2003) 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14:440–447PubMedCrossRef Birck R, Warnatz K, Lorenz HM et al (2003) 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14:440–447PubMedCrossRef
18.
Zurück zum Zitat Boomsma MM, Stegeman CA, van der Leij MJ et al (2000) Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43:2025–2033.https://doi.org/10.1002/1529-0131(200009)43:9〈2025::AID-ANR13〉3.0.CO;2-OPubMedCrossRef Boomsma MM, Stegeman CA, van der Leij MJ et al (2000) Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43:2025–2033.https://​doi.​org/​10.​1002/​1529-0131(200009)43:9〈2025::AID-ANR13〉3.0.CO;2-OPubMedCrossRef
19.
Zurück zum Zitat Boomsma MM, Stegeman CA, Kramer AB et al (2002) Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int 13:74–82PubMedCrossRef Boomsma MM, Stegeman CA, Kramer AB et al (2002) Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos Int 13:74–82PubMedCrossRef
20.
Zurück zum Zitat Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784PubMedCrossRef Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784PubMedCrossRef
21.
Zurück zum Zitat Bourgarit A, Le Toumelin P, Pagnoux C et al (2005) Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84:323–330CrossRef Bourgarit A, Le Toumelin P, Pagnoux C et al (2005) Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 84:323–330CrossRef
22.
Zurück zum Zitat Bremer JP, Ullrich S, Laudien M et al (2010) Methotrexate plus leflunomide for the treatment of relapsingWegener’s granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol 28:67–71PubMed Bremer JP, Ullrich S, Laudien M et al (2010) Methotrexate plus leflunomide for the treatment of relapsingWegener’s granulomatosis. A retrospective uncontrolled study. Clin Exp Rheumatol 28:67–71PubMed
28.
33.
Zurück zum Zitat Comarmond C, Pagnoux C, Khellaf M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270–281. https://doi.org/10.1002/art.37721 PubMedCrossRef Comarmond C, Pagnoux C, Khellaf M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270–281. https://​doi.​org/​10.​1002/​art.​37721 PubMedCrossRef
36.
38.
Zurück zum Zitat Daoud MS, Gibson LE, DeRemee RA et al (1994) Cutaneous Wegener’s granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol 31:605–612PubMedCrossRef Daoud MS, Gibson LE, DeRemee RA et al (1994) Cutaneous Wegener’s granulomatosis: clinical, histopathologic, and immunopathologic features of thirty patients. J Am Acad Dermatol 31:605–612PubMedCrossRef
39.
Zurück zum Zitat DeRemee RA, McDonald TJ, Harrison EG, Coles DT (1976) Wegener’s granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc 51:777–781PubMed DeRemee RA, McDonald TJ, Harrison EG, Coles DT (1976) Wegener’s granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc 51:777–781PubMed
40.
Zurück zum Zitat Devaney KO, Travis WD, Hoffman G et al (1990) Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 14:555–564PubMedCrossRef Devaney KO, Travis WD, Hoffman G et al (1990) Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 14:555–564PubMedCrossRef
41.
Zurück zum Zitat Effelsberg N, Warnatz K, Peter H et al (2011) Treatment with rituximab induces a severe decrease in immunogloubline levels in patients with ANCA positive vasculitis. Ann Rheum Dis 70(Suppl3):623 Effelsberg N, Warnatz K, Peter H et al (2011) Treatment with rituximab induces a severe decrease in immunogloubline levels in patients with ANCA positive vasculitis. Ann Rheum Dis 70(Suppl3):623
42.
Zurück zum Zitat Elmedhem A, Adu D, Savage COS (2003) Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 18:1001–1004PubMedCrossRef Elmedhem A, Adu D, Savage COS (2003) Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 18:1001–1004PubMedCrossRef
43.
Zurück zum Zitat de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group) (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018–2027PubMedCrossRef de Groot K, Adu D, Savage CO, EUVAS (European vasculitis study group) (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 16:2018–2027PubMedCrossRef
44.
Zurück zum Zitat Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371–380PubMedCrossRef Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371–380PubMedCrossRef
46.
Zurück zum Zitat Faurschou M, Sorensen IJ, Mellemkjaer L et al (2008) Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:100–105PubMed Faurschou M, Sorensen IJ, Mellemkjaer L et al (2008) Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35:100–105PubMed
48.
Zurück zum Zitat Faurschou M, Westman K, Rasmussen N et al (2012) Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472–3477. https://doi.org/10.1002/art.34547 PubMedCrossRef Faurschou M, Westman K, Rasmussen N et al (2012) Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472–3477. https://​doi.​org/​10.​1002/​art.​34547 PubMedCrossRef
50.
Zurück zum Zitat Finkielman JD, Merkel PA, Schroeder D et al (2007) Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147:611–619PubMedCrossRef Finkielman JD, Merkel PA, Schroeder D et al (2007) Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147:611–619PubMedCrossRef
55.
Zurück zum Zitat Gayraud M, Guillevin L, le Toumelin P et al (2001) Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675. https://doi.org/10.1002/1529-0131(200103)44:3〈666::AID-ANR116〉3.0.CO;2-APubMedCrossRef Gayraud M, Guillevin L, le Toumelin P et al (2001) Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 44:666–675. https://​doi.​org/​10.​1002/​1529-0131(200103)44:3〈666::AID-ANR116〉3.0.CO;2-APubMedCrossRef
57.
Zurück zum Zitat Gregersen JW, Kristensen T, Krag SRP et al (2012) Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin Exp Rheumatol 30:S39–S47PubMed Gregersen JW, Kristensen T, Krag SRP et al (2012) Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin Exp Rheumatol 30:S39–S47PubMed
58.
Zurück zum Zitat de Groot K, Gross WL, Herlyn K, Reinhold-Keller E (2001) Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 55:31–38PubMed de Groot K, Gross WL, Herlyn K, Reinhold-Keller E (2001) Development and validation of a disease extent index for Wegener’s granulomatosis. Clin Nephrol 55:31–38PubMed
60.
Zurück zum Zitat de Groot K, Harper L, Jayne DRW et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680PubMedCrossRef de Groot K, Harper L, Jayne DRW et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680PubMedCrossRef
62.
Zurück zum Zitat Guillevin L, Fain O, Lhote F et al (1992) Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 35:208–215PubMedCrossRef Guillevin L, Fain O, Lhote F et al (1992) Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome. A prospective, randomized trial in 78 patients. Arthritis Rheum 35:208–215PubMedCrossRef
63.
Zurück zum Zitat Guillevin L, Lhote F, Jarrousse B, Fain O (1992) Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) 143:405–416 Guillevin L, Lhote F, Jarrousse B, Fain O (1992) Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years. Ann Med Interne (Paris) 143:405–416
64.
Zurück zum Zitat Guillevin L, Lhote F, Cohen P et al (1995) Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 38:1638–1645PubMedCrossRef Guillevin L, Lhote F, Cohen P et al (1995) Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 38:1638–1645PubMedCrossRef
65.
Zurück zum Zitat Guillevin L, Cordier JF, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–2198. https://doi.org/10.1002/1529-0131(199712)40:12〈2187::AID-ART12〉3.0.CO;2-HPubMedCrossRef Guillevin L, Cordier JF, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–2198. https://​doi.​org/​10.​1002/​1529-0131(199712)40:12〈2187::AID-ART12〉3.0.CO;2-HPubMedCrossRef
66.
Zurück zum Zitat Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430. https://doi.org/10.1002/1529-0131(199904)42:3〈421::AID-ANR5〉3.0.CO;2-6PubMedCrossRef Guillevin L, Durand-Gasselin B, Cevallos R et al (1999) Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42:421–430. https://​doi.​org/​10.​1002/​1529-0131(199904)42:3〈421::AID-ANR5〉3.0.CO;2-6PubMedCrossRef
72.
Zurück zum Zitat Haubitz M, Kliem V, Koch KM et al (1997) Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 63:1251–1257PubMedCrossRef Haubitz M, Kliem V, Koch KM et al (1997) Renal transplantation for patients with autoimmune diseases: single-center experience with 42 patients. Transplantation 63:1251–1257PubMedCrossRef
73.
Zurück zum Zitat Haubitz M, Koch KM, Brunkhorst R (1998) Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 13:2074–2076PubMedCrossRef Haubitz M, Koch KM, Brunkhorst R (1998) Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 13:2074–2076PubMedCrossRef
74.
Zurück zum Zitat Haubitz M, Schellong S, Göbel U et al (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 41:1835–1844. https://doi.org/10.1002/1529-0131(199810)41:10〈1835::AID-ART16〉3.0.CO;2-QPubMedCrossRef Haubitz M, Schellong S, Göbel U et al (1998) Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 41:1835–1844. https://​doi.​org/​10.​1002/​1529-0131(199810)41:10〈1835::AID-ART16〉3.0.CO;2-QPubMedCrossRef
78.
Zurück zum Zitat Hellmich B, Csernok E, Fredenhagen G, Gross WL (2007) A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 25:S1–S5PubMed Hellmich B, Csernok E, Fredenhagen G, Gross WL (2007) A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 25:S1–S5PubMed
81.
Zurück zum Zitat Henes JC, Henes M, von Wolff M et al (2012) Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network. Clin Exp Rheumatol 30:S53–S56PubMed Henes JC, Henes M, von Wolff M et al (2012) Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network. Clin Exp Rheumatol 30:S53–S56PubMed
84.
Zurück zum Zitat Herrmann K, Gross WL, Moosig F (2012) Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 30:S62–S65PubMed Herrmann K, Gross WL, Moosig F (2012) Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. Clin Exp Rheumatol 30:S62–S65PubMed
86.
Zurück zum Zitat Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMedCrossRef Hoffman GS, Kerr GS, Leavitt RY et al (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMedCrossRef
87.
Zurück zum Zitat Hoffman GS, Leavitt RY, Kerr GS, Fauci AS (1992) The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35:1322–1329PubMedCrossRef Hoffman GS, Leavitt RY, Kerr GS, Fauci AS (1992) The treatment of Wegener’s granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35:1322–1329PubMedCrossRef
88.
Zurück zum Zitat Hoffman GS, Thomas-Golbanov CK, Chan J et al (2003) Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 30:1017–1021PubMed Hoffman GS, Thomas-Golbanov CK, Chan J et al (2003) Treatment of subglottic stenosis, due to Wegener’s granulomatosis, with intralesional corticosteroids and dilation. J Rheumatol 30:1017–1021PubMed
89.
Zurück zum Zitat Hogan SL, Nachman PH, Wilkman AS et al (1996) Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:23–32PubMed Hogan SL, Nachman PH, Wilkman AS et al (1996) Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:23–32PubMed
90.
Zurück zum Zitat Hogan SL, Falk RJ, Chin H et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631PubMedCrossRef Hogan SL, Falk RJ, Chin H et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631PubMedCrossRef
95.
Zurück zum Zitat Holle JU, Herrmann K, Gross WL, Csernok E (2012) Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol 30:S66–S69PubMed Holle JU, Herrmann K, Gross WL, Csernok E (2012) Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol 30:S66–S69PubMed
99.
102.
Zurück zum Zitat Jarrousse B, Guillevin L, Bindi P et al (1993) Increased risk of Pneumocystis carinii pneumonia in patients with Wegener’s granulomatosis. Clin Exp Rheumatol 11:615–621PubMed Jarrousse B, Guillevin L, Bindi P et al (1993) Increased risk of Pneumocystis carinii pneumonia in patients with Wegener’s granulomatosis. Clin Exp Rheumatol 11:615–621PubMed
104.
Zurück zum Zitat Jayne DR, Davies MJ, Fox CJ et al (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137–1139PubMedCrossRef Jayne DR, Davies MJ, Fox CJ et al (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137–1139PubMedCrossRef
105.
Zurück zum Zitat Jayne DR, Chapel H, Adu D et al (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMedCrossRef Jayne DR, Chapel H, Adu D et al (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439PubMedCrossRef
107.
108.
Zurück zum Zitat Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRef Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRef
116.
Zurück zum Zitat Kaplan-Pavlovcic S, Cerk K, Kveder R et al (2003) Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18(Suppl 5):v5–v7PubMedCrossRef Kaplan-Pavlovcic S, Cerk K, Kveder R et al (2003) Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18(Suppl 5):v5–v7PubMedCrossRef
119.
Zurück zum Zitat Kerr GS, Fleisher TA, Hallahan CW et al (1993) Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 36:365–371PubMedCrossRef Kerr GS, Fleisher TA, Hallahan CW et al (1993) Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 36:365–371PubMedCrossRef
122.
Zurück zum Zitat Klemmer PJ, Chalermskulrat W, Reif MS et al (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42:1149–1153PubMedCrossRef Klemmer PJ, Chalermskulrat W, Reif MS et al (2003) Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 42:1149–1153PubMedCrossRef
123.
Zurück zum Zitat Kliem V, Haubitz M, Ehlerding G et al (1997) Outcome of kidney transplantation in patients with systemic autoimmune diseases. Transplant Proc 29:957–958PubMedCrossRef Kliem V, Haubitz M, Ehlerding G et al (1997) Outcome of kidney transplantation in patients with systemic autoimmune diseases. Transplant Proc 29:957–958PubMedCrossRef
128.
Zurück zum Zitat Koselj-Kajtna M, Koselj M, Rott T et al (2002) Infectious complications of immunosuppressive treatment for anti-neutrophil cytoplasm antibody-related vasculitis. Transplant Proc 34:3001–3002PubMedCrossRef Koselj-Kajtna M, Koselj M, Rott T et al (2002) Infectious complications of immunosuppressive treatment for anti-neutrophil cytoplasm antibody-related vasculitis. Transplant Proc 34:3001–3002PubMedCrossRef
129.
Zurück zum Zitat Lamprecht P, Voswinkel J, Lilienthal T et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 41:1303–1307CrossRef Lamprecht P, Voswinkel J, Lilienthal T et al (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 41:1303–1307CrossRef
130.
Zurück zum Zitat Langford CA, Sneller MC, Hallahan CW et al (1996) Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 39:1754–1760PubMedCrossRef Langford CA, Sneller MC, Hallahan CW et al (1996) Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 39:1754–1760PubMedCrossRef
131.
Zurück zum Zitat Langford CA, Talar-Williams C, Sneller MC (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43:1836–1840. https://doi.org/10.1002/1529-0131(200008)43:8〈1836::AID-ANR20〉3.0.CO;2-RPubMedCrossRef Langford CA, Talar-Williams C, Sneller MC (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43:1836–1840. https://​doi.​org/​10.​1002/​1529-0131(200008)43:8〈1836::AID-ANR20〉3.0.CO;2-RPubMedCrossRef
132.
Zurück zum Zitat Lanham JG, Elkon KB, Pusey CD, Hughes GR (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63:65–81CrossRef Lanham JG, Elkon KB, Pusey CD, Hughes GR (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63:65–81CrossRef
133.
Zurück zum Zitat Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMedCrossRef Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMedCrossRef
135.
140.
Zurück zum Zitat Mahr A, Girard T, Agher R, Guillevin L (2001) Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology (Oxford) 40:492–498CrossRef Mahr A, Girard T, Agher R, Guillevin L (2001) Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology (Oxford) 40:492–498CrossRef
144.
Zurück zum Zitat Martinez V, Cohen P, Pagnoux C et al (2008) Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 58:308–317. https://doi.org/10.1002/art.23147 PubMedCrossRef Martinez V, Cohen P, Pagnoux C et al (2008) Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 58:308–317. https://​doi.​org/​10.​1002/​art.​23147 PubMedCrossRef
145.
Zurück zum Zitat Masi AT, Hunder GG, Lie JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100PubMedCrossRef Masi AT, Hunder GG, Lie JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100PubMedCrossRef
146.
Zurück zum Zitat Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with Wegener’s granulomatosis from the American College of Rheumatology Wegener’s Granulomatosis Classification Criteria Cohort. Am J Med 101:129–134PubMedCrossRef Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with Wegener’s granulomatosis from the American College of Rheumatology Wegener’s Granulomatosis Classification Criteria Cohort. Am J Med 101:129–134PubMedCrossRef
147.
Zurück zum Zitat McDermott EM, Powell RJ (1996) Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 55:224–229PubMedPubMedCentralCrossRef McDermott EM, Powell RJ (1996) Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 55:224–229PubMedPubMedCentralCrossRef
150.
Zurück zum Zitat Mekhail TM, Hoffman GS (2000) Longterm outcome of Wegener’s granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 27:1237–1240PubMed Mekhail TM, Hoffman GS (2000) Longterm outcome of Wegener’s granulomatosis in patients with renal disease requiring dialysis. J Rheumatol 27:1237–1240PubMed
151.
Zurück zum Zitat de Menthon M, Cohen P, Pagnoux C et al (2011) Infliximab or rituximab for refractory Wegener’s granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 29:S63–S71PubMed de Menthon M, Cohen P, Pagnoux C et al (2011) Infliximab or rituximab for refractory Wegener’s granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 29:S63–S71PubMed
152.
Zurück zum Zitat Merkel PA, Lo GH, Holbrook JT et al (2005) Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142:620–626PubMedCrossRef Merkel PA, Lo GH, Holbrook JT et al (2005) Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 142:620–626PubMedCrossRef
154.
Zurück zum Zitat Metzler C, Hellmich B, Gause A et al (2004) Churg Strauss syndrome—successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22:S52–S61PubMed Metzler C, Hellmich B, Gause A et al (2004) Churg Strauss syndrome—successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22:S52–S61PubMed
156.
Zurück zum Zitat Metzler C, Schnabel A, Gross WL, Hellmich B (2008) A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 26:S35–S40PubMed Metzler C, Schnabel A, Gross WL, Hellmich B (2008) A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 26:S35–S40PubMed
157.
Zurück zum Zitat Metzler C, Csernok E, Gross WL, Hellmich B (2010) Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 28:24–30PubMed Metzler C, Csernok E, Gross WL, Hellmich B (2010) Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol 28:24–30PubMed
169.
Zurück zum Zitat Muso E, Ito-Ihara T, Ono T et al (2004) Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 57:S17–S18PubMed Muso E, Ito-Ihara T, Ono T et al (2004) Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 57:S17–S18PubMed
170.
Zurück zum Zitat Nachman PH, Hogan SL, Jennette JC, Falk RJ (1996) Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:33–39PubMed Nachman PH, Hogan SL, Jennette JC, Falk RJ (1996) Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 7:33–39PubMed
176.
Zurück zum Zitat Nyberg G, Akesson P, Nordén G, Wieslander J (1997) Kidney transplantation in patients with systemic vasculitis. Transplant Proc 29:235PubMedCrossRef Nyberg G, Akesson P, Nordén G, Wieslander J (1997) Kidney transplantation in patients with systemic vasculitis. Transplant Proc 29:235PubMedCrossRef
178.
Zurück zum Zitat Omdal R, Wildhagen K, Hansen T et al (2005) Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand J Rheumatol 34:229–232PubMedCrossRef Omdal R, Wildhagen K, Hansen T et al (2005) Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand J Rheumatol 34:229–232PubMedCrossRef
180.
Zurück zum Zitat Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33:77–83 Pagnoux C, Carette S, Khalidi NA et al (2015) Comparability of patients with ANCA-associated vasculitis enrolled in clinical trials or in observational cohorts. Clin Exp Rheumatol 33:77–83
181.
Zurück zum Zitat Pagnoux C, Quéméneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 67:1117–1127. https://doi.org/10.1002/art.39011 PubMedCrossRef Pagnoux C, Quéméneur T, Ninet J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 67:1117–1127. https://​doi.​org/​10.​1002/​art.​39011 PubMedCrossRef
186.
190.
Zurück zum Zitat Rasmussen N, Salmela A, Ekstrand A et al (2013) Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener’s) may reflect treatment rather than disease activity. Clin Exp Rheumatol 31:S38–S44PubMed Rasmussen N, Salmela A, Ekstrand A et al (2013) Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener’s) may reflect treatment rather than disease activity. Clin Exp Rheumatol 31:S38–S44PubMed
191.
Zurück zum Zitat Reinhold-Keller E, De Groot K, Rudert H et al (1996) Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. QJM 89:15–23PubMedCrossRef Reinhold-Keller E, De Groot K, Rudert H et al (1996) Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. QJM 89:15–23PubMedCrossRef
197.
Zurück zum Zitat Roccatello D, Baldovino S, Alpa M et al (2008) Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26:67–71 Roccatello D, Baldovino S, Alpa M et al (2008) Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 26:67–71
201.
Zurück zum Zitat Sablé-Fourtassou R, Cohen P, Mahr A et al (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143:632–638PubMedCrossRef Sablé-Fourtassou R, Cohen P, Mahr A et al (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143:632–638PubMedCrossRef
203.
Zurück zum Zitat Savige J, Gillis D, Benson E et al (1999) International consensus statement on testing and reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 111:507–513PubMedCrossRef Savige J, Gillis D, Benson E et al (1999) International consensus statement on testing and reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 111:507–513PubMedCrossRef
204.
Zurück zum Zitat Savige J, Dimech W, Fritzler M et al (2003) Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 120:312–318. https://doi.org/10.1309/WAEP-ADW0-K4LP-UHFN PubMedCrossRef Savige J, Dimech W, Fritzler M et al (2003) Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 120:312–318. https://​doi.​org/​10.​1309/​WAEP-ADW0-K4LP-UHFN PubMedCrossRef
208.
Zurück zum Zitat Schnabel A, Holl-Ulrich K, Dalhoff K et al (1997) Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 10:2738–2743PubMedCrossRef Schnabel A, Holl-Ulrich K, Dalhoff K et al (1997) Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 10:2738–2743PubMedCrossRef
210.
Zurück zum Zitat Schultz H, Csernok E, Herlyn K et al (2003) ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations. Clin Exp Rheumatol 21:117–120 Schultz H, Csernok E, Herlyn K et al (2003) ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations. Clin Exp Rheumatol 21:117–120
212.
Zurück zum Zitat Seo P, Specks U, Keogh KA (2008) Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol 35:2017–2023PubMed Seo P, Specks U, Keogh KA (2008) Efficacy of rituximab in limited Wegener’s granulomatosis with refractory granulomatous manifestations. J Rheumatol 35:2017–2023PubMed
213.
Zurück zum Zitat Sepehr A, Alexander AJ, Chauhan N, Gantous A (2011) Detailed analysis of graft techniques for nasal reconstruction following Wegener granulomatosis. J Otolaryngol 40:473–480 Sepehr A, Alexander AJ, Chauhan N, Gantous A (2011) Detailed analysis of graft techniques for nasal reconstruction following Wegener granulomatosis. J Otolaryngol 40:473–480
214.
225.
Zurück zum Zitat Stone JH, Tun W, Hellman DB (1999) Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 26:1134–1139PubMed Stone JH, Tun W, Hellman DB (1999) Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 26:1134–1139PubMed
232.
Zurück zum Zitat Talar-Williams C, Hijazi YM, Walther MM et al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477–484PubMedCrossRef Talar-Williams C, Hijazi YM, Walther MM et al (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124:477–484PubMedCrossRef
233.
234.
Zurück zum Zitat Tatsis E, Schnabel A, Gross WL (1998) Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129:370–374PubMedCrossRef Tatsis E, Schnabel A, Gross WL (1998) Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129:370–374PubMedCrossRef
240.
Zurück zum Zitat Travis WD, Hoffman GS, Leavitt RY et al (1991) Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 15:315–333PubMedCrossRef Travis WD, Hoffman GS, Leavitt RY et al (1991) Surgical pathology of the lung in Wegener’s granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 15:315–333PubMedCrossRef
257.
258.
Zurück zum Zitat Zycinska K, Romanowska M, Nowak I et al (2007) Antibody response to inactivated subunit influenza vaccine in patients with Wegener’s granulomatosis. J Physiol Pharmacol 58(Suppl 5):819–828PubMed Zycinska K, Romanowska M, Nowak I et al (2007) Antibody response to inactivated subunit influenza vaccine in patients with Wegener’s granulomatosis. J Physiol Pharmacol 58(Suppl 5):819–828PubMed
Metadaten
Titel
S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
verfasst von
Dr. Jan Henrik Schirmer
Peer M. Aries
Kirsten de Groot
Bernhard Hellmich
Julia U. Holle
Christian Kneitz
Ina Kötter
Peter Lamprecht
Ulf Müller-Ladner
Eva Reinhold-Keller
Christof Specker
Michael Zänker
Frank Moosig
Publikationsdatum
04.12.2017

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.